See more : National Beverage Corp. (FIZZ) Income Statement Analysis – Financial Results
Complete financial analysis of Kymera Therapeutics, Inc. (KYMR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kymera Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Tainergy Tech Co., Ltd. (4934.TW) Income Statement Analysis – Financial Results
- LegalZoom.com, Inc. (LZ) Income Statement Analysis – Financial Results
- Salazar Resources Limited (SRLZF) Income Statement Analysis – Financial Results
- Tuan Sing Holdings Limited (T24.SI) Income Statement Analysis – Financial Results
- SouthCorp Capital, Inc. (STHC) Income Statement Analysis – Financial Results
Kymera Therapeutics, Inc. (KYMR)
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 78.59M | 46.83M | 72.83M | 34.03M | 2.93M | 0.00 |
| Cost of Revenue | 189.08M | 2.98M | 2.40M | 62.11M | 825.00K | 205.00K |
| Gross Profit | -110.49M | 43.85M | 70.44M | -28.07M | 2.11M | -205.00K |
| Gross Profit Ratio | -140.59% | 93.64% | 96.71% | -82.48% | 71.88% | 0.00% |
| Research & Development | 189.08M | 164.25M | 137.02M | 62.11M | 37.16M | 17.68M |
| General & Administrative | 55.04M | 43.83M | 36.35M | 18.23M | 7.98M | 3.77M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 55.04M | 43.83M | 36.35M | 18.23M | 7.98M | 3.77M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 244.12M | 208.08M | 173.36M | 80.34M | 45.14M | 21.45M |
| Cost & Expenses | 244.12M | 208.08M | 173.36M | 80.34M | 45.14M | 21.45M |
| Interest Income | 18.76M | 6.62M | 488.00K | 826.00K | 1.01M | 0.00 |
| Interest Expense | 196.00K | 176.00K | 175.00K | 115.00K | 46.00K | 16.00K |
| Depreciation & Amortization | 3.57M | 2.98M | 2.40M | 1.76M | 825.00K | 205.00K |
| EBITDA | -143.20M | -151.66M | -97.65M | -43.72M | -40.38M | -21.25M |
| EBITDA Ratio | -182.21% | -330.23% | -137.36% | -133.63% | -1,376.11% | 0.00% |
| Operating Income | -165.53M | -161.26M | -100.53M | -46.30M | -42.21M | -21.45M |
| Operating Income Ratio | -210.62% | -344.37% | -138.03% | -136.05% | -1,438.48% | 0.00% |
| Total Other Income/Expenses | 18.57M | 6.45M | 313.00K | 711.00K | 959.00K | -16.00K |
| Income Before Tax | -146.96M | -154.81M | -100.22M | -45.59M | -41.25M | -21.47M |
| Income Before Tax Ratio | -186.99% | -330.60% | -137.60% | -133.96% | -1,405.79% | 0.00% |
| Income Tax Expense | 0.00 | -2.98M | -2.22M | -1.65M | 46.00K | 43.86K |
| Net Income | -146.96M | -151.83M | -98.00M | -43.95M | -41.29M | -21.47M |
| Net Income Ratio | -186.99% | -324.25% | -134.55% | -129.12% | -1,407.36% | 0.00% |
| EPS | -2.52 | -2.82 | -2.04 | -2.53 | -0.93 | -0.48 |
| EPS Diluted | -2.52 | -2.82 | -2.04 | -2.53 | -0.93 | -0.48 |
| Weighted Avg Shares Out | 58.37M | 53.93M | 47.99M | 17.35M | 44.53M | 44.53M |
| Weighted Avg Shares Out (Dil) | 58.37M | 53.93M | 47.99M | 17.35M | 44.53M | 44.53M |
Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
Source: https://incomestatements.info
Category: Stock Reports